| Literature DB >> 32801702 |
Xuan Zhu1,2,3, Qingquan Kong2, Xing Niu4, Lijie Chen4, Chunlin Ge1.
Abstract
OBJECTIVE: To comprehensively analyze the global scientific outputs of nanoparticles in pancreatic cancer research.Entities:
Keywords: CiteSpace; Web of Science; co-citation analysis; co-word analysis; nanoparticles; pancreatic cancer
Mesh:
Year: 2020 PMID: 32801702 PMCID: PMC7415461 DOI: 10.2147/IJN.S253599
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Major topics for the nanoparticles in pancreatic cancer. (A and B) Visualization of keyword ranking based on the carrot system. The larger the weight of the topic, the larger the area, and the more central the module. (C) Density visualization. (D) Keyword co-occurrence map visualization. Bubble chart visualized 219 keywords. The minimum number of occurrences of a keyword was set as 10. The bigger the bubble, the higher the frequency. Furthermore, the closer the proximity, the higher the frequency.
Figure 2Publication years (A) and publication types (B).
Highly Frequent Terms in the Nanoparticles in Pancreatic Cancer
| No. | Keywords | Frequency, n | Percentage, % | Cumulative Percentage, % |
|---|---|---|---|---|
| 1 | Pancreatic cancer | 148 | 3.2132 | 3.2132 |
| 2 | Pancreatic cancer | 113 | 2.4533 | 5.6665 |
| 3 | Nanoparticles | 57 | 1.2375 | 6.9040 |
| 4 | Nanoparticles | 56 | 1.2158 | 8.1198 |
| 5 | Drug delivery | 56 | 1.2158 | 9.3356 |
| 6 | Gemcitabine | 49 | 1.0638 | 10.3995 |
| 7 | Drug delivery | 37 | 0.8033 | 11.2028 |
| 8 | Gemcitabine | 35 | 0.7599 | 11.9627 |
| 9 | Cancer | 31 | 0.6730 | 12.6357 |
| 10 | Nanomedicine | 25 | 0.5428 | 13.1785 |
| 11 | Cancer | 25 | 0.5428 | 13.7212 |
| 12 | Nanoparticle | 23 | 0.4993 | 14.2206 |
| 13 | Nanoparticle | 22 | 0.4776 | 14.6982 |
| 14 | Nanomedicine | 21 | 0.4559 | 15.1541 |
| 15 | Magnetic resonance imaging | 20 | 0.4342 | 15.5884 |
| 16 | Gold nanoparticles | 19 | 0.4125 | 16.0009 |
| 17 | Apoptosis | 18 | 0.3908 | 16.3917 |
| 18 | Nanotechnology | 17 | 0.3691 | 16.7607 |
| 19 | Curcumin | 15 | 0.3257 | 17.0864 |
| 20 | Gold nanoparticles | 15 | 0.3257 | 17.4121 |
Figure 3Clustering analysis of high frequently journals in the nanoparticles in pancreatic cancer. (A) The country distribution of cited papers related with the nanoparticles in pancreatic cancer. (B) A mountain visualization biclustering of highly frequent journals and articles on the nanoparticles in pancreatic cancer. (C) A visualized matrix biclustering of highly frequent journals and PubMed Unique Identifiers of articles related with the nanoparticles in pancreatic cancer.
Highly Frequent Journals in the Nanoparticles in Pancreatic Cancer
| No. | Journals | Frequency, n | Percentage, % | Cumulative Percentage, % |
|---|---|---|---|---|
| 1 | Journal of Controlled Release | 45 | 3.8429 | 3.8429 |
| 2 | International Journal of Nanomedicine | 45 | 3.8429 | 7.6857 |
| 3 | ACS nano | 44 | 3.7575 | 11.4432 |
| 4 | Biomaterials | 39 | 3.3305 | 14.7737 |
| 5 | RSC Advances | 27 | 2.3057 | 17.0794 |
| 6 | International Journal of Pharmaceutics | 24 | 2.0495 | 19.1289 |
| 7 | Journal of Materials Chemistry B | 23 | 1.9641 | 21.0931 |
| 8 | ACS Applied Materials & Interfaces | 23 | 1.9641 | 23.0572 |
| 9 | Nanomedicine-Nanotechnology Biology and Medicine | 23 | 1.9641 | 25.0213 |
| 10 | Cancer Research | 23 | 1.9641 | 26.9855 |
| 11 | Theranostics | 19 | 1.6225 | 28.6080 |
| 12 | Molecular Pharmaceutics | 18 | 1.5371 | 30.1452 |
| 13 | Nanoscale | 16 | 1.3664 | 31.5115 |
| 14 | Scientific Reports | 16 | 1.3664 | 32.8779 |
| 15 | Journal of Biomedical Nanotechnology | 15 | 1.2810 | 34.1588 |
| 16 | Colloids and Surfaces B-Biointerfaces | 14 | 1.1956 | 35.3544 |
| 17 | Small | 14 | 1.1956 | 36.5500 |
| 18 | PLoS One | 14 | 1.1956 | 37.7455 |
| 19 | Nanomedicine | 14 | 1.1956 | 38.9411 |
| 20 | Bioconjugate Chemistry | 13 | 1.1102 | 40.0512 |
Highly Frequent Cited Journals in the Nanoparticles in Pancreatic Cancer
| No. | Journals | Frequency, n | Percentage, % | Cumulative Percentage, % |
|---|---|---|---|---|
| 1 | Biomaterials | 1918 | 2.9466 | 2.9466 |
| 2 | J Control Release | 1899 | 2.9175 | 5.8641 |
| 3 | Cancer Res | 1755 | 2.6962 | 8.5603 |
| 4 | Acs nano | 1393 | 2.1401 | 10.7004 |
| 5 | P Natl Acad Sci USA | 1083 | 1.6638 | 12.3642 |
| 6 | Adv Drug Deliver Rev | 1048 | 1.6101 | 13.9743 |
| 7 | J Am Chem Soc | 1038 | 1.5947 | 15.5690 |
| 8 | Clin Cancer Res | 915 | 1.4057 | 16.9747 |
| 9 | Int J Nanomed | 753 | 1.1568 | 18.1315 |
| 10 | INT J PHARMACEUT | 703 | 1.0800 | 19.2116 |
| 11 | Nano Lett | 653 | 1.0032 | 20.2148 |
| 12 | J Clin Oncol | 608 | 0.9341 | 21.1489 |
| 13 | Science | 601 | 0.9233 | 22.0722 |
| 14 | Nature | 600 | 0.9218 | 22.9940 |
| 15 | Mol Pharmaceut | 571 | 0.8772 | 23.8712 |
| 16 | PLoS One | 556 | 0.8542 | 24.7254 |
| 17 | Nat Rev Cancer | 529 | 0.8127 | 25.5381 |
| 18 | Bioconjugate Chem | 522 | 0.8020 | 26.3400 |
| 19 | Angew Chem Int Edit | 489 | 0.7513 | 27.0913 |
| 20 | Small | 480 | 0.7374 | 27.8287 |
Highly Frequent Cited Papers in the Nanoparticles in Pancreatic Cancer
| No. | Articles | Frequency, n | Percentage, % | Cumulative Percentage, % |
|---|---|---|---|---|
| 1 | Burris HA, 1997, J Clin Oncol, V15, P2403 | 66 | 0.1014 | 0.1014 |
| 2 | Von Hoff DD, 2013, New Engl J Med, V369, P1691 | 62 | 0.0953 | 0.1966 |
| 3 | Matsumura Y, 1986, Cancer Res, V46, P6387 | 61 | 0.0937 | 0.2904 |
| 4 | Peer D, 2007, Nat Nanotechnol, V2, P751 | 56 | 0.0860 | 0.3764 |
| 5 | Cabral H, 2011, Nat Nanotechnol, V6, P815 | 55 | 0.0845 | 0.4609 |
| 6 | Olive KP, 2009, Science, V324, P1457 | 49 | 0.0753 | 0.5362 |
| 7 | Jain RK, 2010, Nat Rev Clin Oncol, V7, P653 | 47 | 0.0722 | 0.6084 |
| 8 | Lee GY, 2013, ACS nano, V7, P2078 | 44 | 0.0676 | 0.6760 |
| 9 | Patra CR, 2008, Cancer Res, V68, P1970 | 44 | 0.0676 | 0.7436 |
| 10 | Maeda H, 2000, J Control Release, V65, P271 | 42 | 0.0645 | 0.8081 |
| 11 | Provenzano PP, 2012, Cancer Cell, V21, P418 | 42 | 0.0645 | 0.8726 |
| 12 | Conroy T, 2011, New Engl J Med, V364, P1817 | 41 | 0.0630 | 0.9356 |
| 13 | Meng H, 2015, ACS nano, V9, P3540 | 41 | 0.0630 | 0.9986 |
| 14 | Hidalgo M, 2010, New Engl J Med, V362, P1605 | 40 | 0.0615 | 1.0601 |
| 15 | Davis ME, 2008, Nat Rev Drug Discov, V7, P771 | 39 | 0.0599 | 1.1200 |
| 16 | Ferrari M, 2005, Nat Rev Cancer, V5, P161 | 36 | 0.0553 | 1.1753 |
| 17 | Fang J, 2011, Adv Drug Deliver Rev, V63, P136 | 35 | 0.0538 | 1.2290 |
| 18 | Erkan M, 2012, Nat Rev Gastro Hepat, V9, P454 | 32 | 0.0492 | 1.2782 |
| 19 | Li DH, 2004, Lancet, V363, P1049 | 31 | 0.0476 | 1.3258 |
| 20 | Siegel R, 2014, CA-Cancer J Clin, V64, P9 | 31 | 0.0476 | 1.3735 |
Descriptive and Discriminating Features in the Eight Clusters
| Cluster | Size | Internal Similarity | Internal Standard Deviation | External Similarity | External Standard Deviation |
|---|---|---|---|---|---|
| 0 | 7 | 0.386 | 0.038 | 0.180 | 0.030 |
| 1 | 19 | 0.380 | 0.046 | 0.181 | 0.049 |
| 2 | 8 | 0.350 | 0.039 | 0.176 | 0.041 |
| 3 | 6 | 0.290 | 0.020 | 0.129 | 0.034 |
| 4 | 19 | 0.372 | 0.060 | 0.211 | 0.063 |
| 5 | 9 | 0.293 | 0.026 | 0.157 | 0.025 |
| 6 | 18 | 0.304 | 0.029 | 0.180 | 0.034 |
| 7 | 20 | 0.315 | 0.069 | 0.191 | 0.066 |
Highly Frequent Cited Authors in the Nanoparticles in Pancreatic Cancer
| No. | Authors | Frequency, n | Percentage, % | Cumulative Percentage, % |
|---|---|---|---|---|
| 1 | Yong, KT | 29 | 0.3458 | 0.3458 |
| 2 | Wang, J | 23 | 0.2742 | 0.6200 |
| 3 | Zhang, Y | 17 | 0.2027 | 0.8227 |
| 4 | Roy, I | 17 | 0.2027 | 1.0254 |
| 5 | Couvreur, P | 16 | 0.1908 | 1.2162 |
| 6 | Prasad, PN | 16 | 0.1908 | 1.4069 |
| 7 | Wang, Y | 14 | 0.1669 | 1.5739 |
| 8 | Yallapu, MM | 14 | 0.1669 | 1.7408 |
| 9 | Jaggi, M | 14 | 0.1669 | 1.9077 |
| 10 | Kataoka, K | 14 | 0.1669 | 2.0746 |
| 11 | Chauhan, SC | 14 | 0.1669 | 2.2416 |
| 12 | Huang, L | 13 | 0.1550 | 2.3966 |
| 13 | Yang, L | 13 | 0.1550 | 2.5516 |
| 14 | Fu, DL | 13 | 0.1550 | 2.7066 |
| 15 | Li, J | 13 | 0.1550 | 2.8616 |
| 16 | Khan, S | 13 | 0.1550 | 3.0166 |
| 17 | Hu, R | 12 | 0.1431 | 3.1597 |
| 18 | Mao, H | 12 | 0.1431 | 3.3027 |
| 19 | Wang, LY | 12 | 0.1431 | 3.4458 |
| 20 | Jin, C | 12 | 0.1431 | 3.5889 |
Figure 4Citation burst. (A and B) Clustering analysis of the nanoparticles in pancreatic cancer co-citation network, generated by top 50 per slice between 1986 and 2019. (LRF = 3.0, LBY = 8, and e = 2.0). The size of the node represents the number of times of the cited literature, and the color of the line expresses the time when an article is first cited. Red text stands for the terms extracted from the title of the citing article in each cluster. (C) The top 20 references with the strongest citation bursts in the co-citation network.
Figure 5A timeline visualization from 2000 to 2018. Nodes are labeled with corresponding topics.
Figure 6Discipline and journal analysis. (A) Dual-map overlap of the nanoparticles in pancreatic cancer literature. The colored curve suggests the reference path. The nature of each region is defined by the Journal of the corresponding region. (B) The top 20 journals according to cited records in the field of the nanoparticles in pancreatic cancer.
Figure 7Citation networks. (A) Citation network of the 132 most cited publications from 2003 to 2017. (B) Citation network of the 10 most cited publications from 2008 to 2012. The curves between the nodes suggest the citation relationships.
Figure 8Co-cited publication cluster analysis. (A) Co-cited publication density map based on co-citation. (B) Co-cited publication network.
Figure 9Co-citation map of authors and institutions on clustered networks. Co-cited author network (A) and co-cited institution network (B), generated by top 20 per slice between 1986 and 2019 (LRF = 3.0, LBY = 8, and e = 2.0). The size of the nodes in the network indicates the amount of publications by authors or institutions.